Biogen and Sage to scrap neurological disorder drug development after trial failure (updated)

Sage Therapeutics

24/07/2024 11:49

(Adds details paragraph 2 onwards)
       July 24 (Reuters) - Biogen  BIIB.O  and Sage
Therapeutics  SAGE.O  do not plan to conduct further studies for
their neurological disorder drug after it failed in a mid-stage
trial, the drugmakers said on Wednesday.
    The experimental drug, SAGE-324, was being studied as a
treatment for essential tremor, a disorder that causes
uncontrollable shaking of the hands, arms and other body parts.
    The drug failed to show statistically significant
dose-response relationship, as measured on a scale, for upper
limb tremor.
    The companies said they were planning the next steps, if
any, to study the drug in other potential conditions.

 (Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi
Majumdar)
 ((Sriparna.Roy@thomsonreuters.com))